Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia

Neurobiology of Disease

Volumn 40, Issue 3, 2010, Pages 599-607

  Zeng, Bai Yun ^a   Iravani, Mahmoud M ^a   Jackson, Michael J ^a   Rose, Sarah ^a   Parent, André ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

Author keywords

Dyskinesia; L DOPA; Primate; Serotonin; Tryptophan hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA; TRYPTOPHAN HYDROXYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC INNERVATION; CAUDATE NUCLEUS; CELL COUNT; CELL ENLARGEMENT; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; MALE; MARMOSET; NERVE FIBER; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; SEROTONINERGIC NERVE CELL;

ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; CORPUS STRIATUM; DYSKINESIA, DRUG-INDUCED; FEMALE; GLOBUS PALLIDUS; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; NEURITES; PARKINSONIAN DISORDERS; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 77957802624     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.08.004     Document Type: Article

References (54)

1. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res. 1994, 667:295-299.
2. Arai R., Karasawa N., Geffard M., Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a doublelabeling immunofluorescence study. Neurosci. Lett. 1995, 195:195-198.
3. Boyce S., Rupniak N.M.J., Steventon M.J., Iversen S.D. Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin. Neuropharmacol. 1990, 13:448-458.
4. Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., Bannister R., Marsden C.D., Frackowiak R.S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 1990, 28:547-555.
5. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
6. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology 1998, 51:S30-S35.
7. Conti C.F., de Oliveira M.M., Andriolo R.B., Saconato H., Atallah A.N., Valbuza J.S., Coin de Carvalho L.B., do Prado G.F. Levodopa for idiopathic restless legs syndrome: evidence-based review. Mov. Disord. 2007, 22:1943-1951.
8. Cotzias G.C., Van Woert M.H., Schiffer L.M. Aromatic amino acids and modification of parkinsonism. N Engl J. Med. 1967, 276:374-379.
9. Craven R.M., Priddle T.H., Cooper S.J., Crow T.J., Esiri M.M. The dorsal raphe nucleus in schizophrenia: a post mortem study of 5-hydroxytryptamine neurones. Neuropathol. Appl. Neurobiol. 2005, 31:258-269.
10. Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000, 95(2):399-408.
11. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
12. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 2000, 47:S2-S11.
13. Gaspar P., Febvret A., Colombo J. Serotonergic sprouting in primate MPTP-induced hemiparkinsonism. Exp. Brain Res. 1993, 96:100-106.
14. Goetz C.G., Damier P., Hicking C., Laska E., Müller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 2007, 22:179-186.
15. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., Di Paulo T. Low doses of sarizotan reduces dyskinesia and maintain antiparkinsonian efficacy of L-DOPA in parkinsonian monkeys. Parkinsonism Rel. Disord. 2009, 15:445-452.
16. Hollister A.S., Breese G.R., Mueller R.A. Role of monoamine neural systems in l-dihydroxyphenylalanine-stimulated activity. J. Pharmacol. Exp. Ther. 1979, 208:37-43.
17. Hornung J.P., Fritschy J.M., Tork I. Distribution of two morphologically distinct subsets of serotoninergic axons in the cerebral cortex of marmoset. J. Comp. Neurol. 1990, 297:165-181.
18. Iravani M.M., Jackson M.J., Kuoppamäki M., Smith L.A., Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 2003, 23:9107-9115.
19. Iravani M.M., Costa S., Al-Barghouthy G., Jackson M.J., Zeng B.-Y., Kuoppamäki M., Obeso J.A., Jenner P. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. Eur. J. Neurosci. 2005, 22:1305-1318.
20. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. J. Pharmacol. Exp. Ther. 2006, 319:1225-1234.
21. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62(Suppl 1):S47-S55.
22. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat. Rev. Neurosci. 2008, 9(9):665-677.
23. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., Marsden C.D. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 1984, 50:85-90.
24. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J. Med. 1988, 318:876-880.
25. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
26. Lavoie B., Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 1990, 299:1-16.
27. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 2003, 343:17-20.
28. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 2005, 1046:230-233.
29. Marin C., Aguilar E., Rodríguez-Oroz M.C., Bartoszyk G.D., Obeso J.A. Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Psychopharmacology (Berl) 2009, 204:241-250.
30. Mones R.J., Elizan T.S., Siegel G.J. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J. Neurol. Neurosurg. Psychiatry 1971, 34:668-673.
31. Mori S., Ueda S., Yamada H., Takino T., Sano Y. Immunohistochemical demonstration of serotonin nerve fibers in the corpus striatum of the rat, cat and monkey. Anat Embryol (Berl) 1985, 173:1-5.
32. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Luca M.D., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
33. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1a and 5-HT1b receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
34. Ng K.Y., Chase T.N., Colburn R.W., Kopin I.J. L-Dopa-induced release of cerebral monoamines. Science 1970, 170:76-77.
35. Ng K.Y., Colburn R.W., Kopin I.J. Effects of L-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971, 230:331-332.
36. Nutt J.G. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990, 40:340-345.
37. Obeso J.A., Rodríguez-Oroz M.C., Rodríguez M., Lanciego J.L., Artieda J., Gonzalo N., Olanow C.W. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000, 23(Suppl):S8-S19.
38. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 1998, 8:2788-2803.
39. Olanow C.W., Obeso J.A., Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat. Clin. Pract. Neurol. 2006, 2:382-392.
40. Paulson G.W. Dyskinesias in monkeys. Advances in Neurology 1973, vol. 1:647-650. Raven Press, New York. A. Barbeau, T.N. Chase, G.W. Paulson (Eds.).
41. Pearce R.K., Heikkilä M., Lindén I.B., Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 2001, 156:402-409.
42. Peter D., Liu Y., de Giorgio R., Brecha N., Edwards R.H. Differential expression of two vesicular monoamine transporters. J. Neurosci. 1995, 15:6179-6188.
43. Rajput A.H., Fenton M., Birdi S., Macaulay R. Is levodopa toxic to human substantia nigra?. Mov. Disord. 1997, 12:634-638.
44. Rozas G., Liste I., Guerra M.J., Labandeira-Garcia J.L. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci. Lett. 1998, 245:151-154.
45. Sassin J.F. Drug-induced dyskinesia in monkeys. Advances in Neurology 1975, vol. 10:47-54. Raven Press, New York. B.S. Meldrum, C.D. Marsden (Eds.).
46. Schneider J.S. Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 1989, 34:193-196.
47. Stephan H., Baron G., Schwerdtreger W.K. The brain of the common marmoset (Callithrix jacchus): a stereotaxic atlas 1980, Springer-Verlag, Berlin.
48. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. NeuroReport 1999, 10:631-634.
49. Taylor J.L., Bishop C., Ullrich T., Rice K.C., Walker P.D. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 2006, 50:761-768.
50. Van Bockstaele E.J., Pickel V.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interaction with catecholamine afferents. J. Comp. Neurol. 1993, 334:603-617.
51. Vanover K.E., Betz A.J., Weber S.M., Bibbiani F., Kielaite A., Weiner D.M., Davis R.E., Chase T.N., Salamone J.D. A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol. Biochem. Behav. 2008, 90:540-544.
52. Zesiewicz T.A., Sullivan K.L., Hauser R.A. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Curr. Neurol. Neurosci. Rep. 2007, 7:302-310.
53. Zhang X., Andren P.E., Greengard P., Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc. Natl Acad. Sci. USA 2008, 12:2163-2168.
54. Zhou F.C., Bledsoe S., Murphy J. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 1991, 556:108-116.